CT-155 is a smartphone app that integrates psychosocial interventions delivered using an adaptive goal-setting technique. A ...

Zongertinib received FDA approval for HER2-mutant NSCLC, showing efficacy in first-line treatment with a 77% objective ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...

Bimeda US recently announced the launch of Gamrozyne ™, the first and only bioequivalent to Zactran ® (Boehringer-Ingelheim ® ...

Deals: Novo Nordisk is set to buy a blood disease drug from Omeros for up to $2.1 billion. Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion. Boehringer Ingelhei ...

Antibody-drug conjugate (ADC) specialist Aimedbio Inc. announced Oct. 16 the signing of a potential $991 million deal with ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

The U.S. Court of Appeals for the Eleventh Circuit heard oral arguments on Friday about whether to reverse a 2022 ruling ...

With only $41 million in cash, Tvardi Therapeutics may need to raise additional funds within a one-year period. Click here to ...